Skip to main content

Market Overview

Charles River Laboratories Is A Leader In Biopharma Outsourcing, KeyBanc Says In Upgrade

Share:
Charles River Laboratories Is A Leader In Biopharma Outsourcing, KeyBanc Says In Upgrade

Charles River Laboratories Intl. Inc (NYSE: CRL), a preclinical and clinical laboratory service provider to the pharmaceutical, medical device and biotechnology industries, is "by far" an industry leader, according to KeyBanc Capital Markets. 

The Analyst

Analyst Donald Hooker upgraded Charles River Laboratories from Sector Weight to Overweight with a new $130 price target.

The Thesis

Charles River boasts the "most comprehensive" set of preclinical research products and services, which makes it a strategic outsourcing partner that its peers can't match, Hooker said in the upgrade note.

The company's strategic positioning should help it sustain 6 percent or more revenue growth over the next three years along with expanding operating margins derived from up to $16 million in cost synergies tied to the early 2018 acquisition of MPO Research.

Investor concerns over the "sensitivity of biopharma R&D to capital market conditions" are overblown, the analyst said. A "friendly" regulatory environment and the absence of internal capacity at major biopharmaceutical companies makes it unlikely preclinical research will be insourced again, he said. 

Charles River's stock doesn't accurately reflect its strategic positioning, as its valuation remained "stable" at a time when the valuation of many peers rose "significantly," Hooker said. The disconnect creates an attractive opportunity for investors, with Charles River's stock trading at a 13-percent discount to the comparison group versus a historical average of a 7-percent premium.

Price Action

Charles River Laboratories shares were trading higher by 0.5 percent premarket Friday. 

Related Links:

Lab Stocks: Baird Favors Laboratory Corp., Says Quest Diagnostics Is The Simple Choice

KeyBanc Projects 'Significant' Consolidation In Lab Testing Sector

Latest Ratings for CRL

DateFirmActionFromTo
Feb 2022CitigroupUpgradesNeutralBuy
Feb 2022Morgan StanleyMaintainsOverweight
Feb 2022KeybancMaintainsOverweight

View More Analyst Ratings for CRL

View the Latest Analyst Ratings

 

Related Articles (CRL)

View Comments and Join the Discussion!

Posted-In: Donald Hooker KeyBanc Capital MarketsAnalyst Color Biotech Upgrades Price Target Analyst Ratings General Best of Benzinga

Latest Ratings

StockFirmActionPT
SEDGB of A SecuritiesMaintains411.0
PTLOPiper SandlerMaintains28.0
AOUTLake StreetMaintains26.0
RAPTPiper SandlerMaintains52.0
OCXLake StreetMaintains6.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com